Differential action of secreto-inhibitors on proopiomelanocortin biosynthesis in the intermediate pituitary of Xenopus laevis.
In the South African clawed toad Xenopus laevis, background adaptation is regulated by alpha MSH, a POMC-derived peptide. After transfer of the animal from a black to a white background, secretion of alpha MSH from the intermediate pituitary lobe is inhibited by the hypothalamic neurotransmitter neuropeptide Y (NPY). The neurointermediate lobe in vitro is also subject to inhibitory regulation by dopamine and gamma-aminobutyric acid (GABA). In the nerve terminals contacting the intermediate lobe of the pituitary, GABA is contained in electron-lucent vesicles, whereas dopamine and NPY coexist in electron-dense vesicles. To study the role of these secreto-inhibitors in the regulation of POMC biosynthesis, the rate of incorporation of radioactive amino acids into POMC protein was determined after in vitro treatment of the neurointermediate pituitary with NPY, apomorphine (dopamine D2 receptor agonist), isoguvacine (GABAA receptor agonist) and baclofen (GABAB receptor agonist). After 24 h of treatment, inhibition of POMC biosynthesis by NPY and apomorphine was 77% and 74%, respectively. Isoguvacine treatment resulted in an inhibition of 59%, whereas no significant effect of baclofen was observed. When neurointermediate lobes were treated for 3 days, inhibition of POMC biosynthesis by NPY was maintained, and inhibition by apomorphine was even stronger, whereas isoguvacine gave an inhibition of 52%, and baclofen produced 34% inhibition. Superfusion experiments on alpha MSH secretion showed that prolonged treatment with the GABA receptor agonists results in a desensitization of GABA receptor-mediated signal transduction mechanisms, whereas the NPY receptor does not show desensitization. The observations indicate differential actions of the secreto-inhibitors NPY, apomorphine, and GABA agonists on POMC biosynthesis in the Xenopus intermediate pituitary, suggesting a major role for dopamine and NPY, whereas GABA, acting via two receptor types, does not seem to have a major function in long term control of POMC biosynthesis.
Dotman
C H
CH
Department of Cellular Animal Physiology, Nijmegen Institute for Neurosciences, University of Nijmegen, The Netherlands. chdotman@sci.kun.nl
Cruijsen
P M
PM
Jenks
B G
BG
Roubos
E W
EW
D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001418:Baclofen / Q000494:pharmacology*; D018755:GABA Agonists / Q000494:pharmacology; D058785:GABA-A Receptor Agonists; D058786:GABA-B Receptor Agonists; D066298:In Vitro Techniques; D007539:Isonicotinic Acids / Q000494:pharmacology*; D007700:Kinetics; D009478:Neuropeptide Y / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D011333:Pro-Opiomelanocortin / Q000096:biosynthesis*; D017448:Receptors, Dopamine D2 / Q000819:agonists; D014982:Xenopus laevis; D000521:alpha-MSH / Q000096:biosynthesis*
D018755:GABA Agonists; D058785:GABA-A Receptor Agonists; D058786:GABA-B Receptor Agonists; D007539:Isonicotinic Acids; D009478:Neuropeptide Y; D017448:Receptors, Dopamine D2; D000521:alpha-MSH; D011333:Pro-Opiomelanocortin; D001418:Baclofen; D001058:Apomorphine; C015300:isoguvacine